La. Magee et al., Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials, EUR J OB GY, 88(1), 2000, pp. 15-26
Citations number
64
Categorie Soggetti
Reproductive Medicine
Journal title
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY
Objective: Examine the benefits/risks of beta-blockers for pregnancy hypert
ension. Study design: Meta-analysis of relevant trials identified by compre
hensive literature review (1966-97). Results: Included were 30 trials for p
regnancy hypertension, and four others for perinatal outcomes only. For mil
d chronic hypertension treated throughout pregnancy (n=2 trials), oral beta
-blockers (compared with no therapy) were associated with an inconsistent i
ncrease in small for gestational age (SGA) infants (OR 2.46 [1.02, 5.92]),
For mild-moderate 'late-onset' pregnancy hypertension (i.e. either chronic
treated only late in pregnancy, or pregnancy-induced) (n=8 trials), oral be
ta-blockers (compared with no therapy) were associated with a decrease in s
evere hypertension (OR 0.27 [0.16, 0.45]), borderline decrease in developme
nt of proteinuria (OR 0.69 [0.48, 1.02]), decrease in RDS (OR 0.33 [0.13, 0
.85]), but a borderline increase in SGA infants (OR 1.47 [0.96, 2.26]), bet
a-blockers were equivalent to other agents (n=15 trials). For severe 'late-
onset' pregnancy hypertension (n=5 trials), i.v. labetalol produced less ma
ternal hypotension (OR 0.13 [0.03, 0.71]) and fewer cesareans (OR 0.23 [0.1
3, 0.63]) than i.v. hydralazine/diazoxide. Conclusions: It is not clear tha
t the benefits outweigh the risks when beta-blockers are used to treat mild
to moderate chronic or pregnancy-induced hypertension, given the unknown o
verall effect on perinatal outcomes. For severe 'late-onset' pregnancy hype
rtension, i.v. labetalol is safer than i.v. hydralazine or diazoxide, (C) 2
000 Elsevier Science Ireland Ltd. All rights reserved.